ValuEngine downgraded shares of Galapagos (NASDAQ:GLPG) from a hold rating to a sell rating in a research report released on Friday.
Other equities analysts also recently issued research reports about the stock. Cowen reissued a buy rating on shares of Galapagos in a research note on Thursday, August 10th. Nomura increased their price objective on shares of Galapagos from $108.00 to $124.00 and gave the company a buy rating in a research note on Friday, August 11th. Stifel Nicolaus raised shares of Galapagos from a hold rating to a buy rating and increased their price objective for the company from $83.00 to $101.00 in a research note on Friday, August 11th. BTIG Research reissued a buy rating and issued a $118.00 price objective on shares of Galapagos in a research note on Monday, November 20th. Finally, BidaskClub raised shares of Galapagos from a sell rating to a hold rating in a research note on Thursday, August 17th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company. The company has an average rating of Hold and a consensus price target of $111.00.
Shares of Galapagos (NASDAQ:GLPG) traded down $0.66 during trading hours on Friday, reaching $86.59. 41,267 shares of the company traded hands, compared to its average volume of 150,622. Galapagos has a fifty-two week low of $57.86 and a fifty-two week high of $104.12.
WARNING: “Galapagos (GLPG) Downgraded by ValuEngine” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.com-unik.info/2017/12/04/galapagos-glpg-downgraded-by-valuengine.html.
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about Galapagos NV? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Galapagos NV and related companies.